Wuhan Hiteck Biological Pharma Co Ltd (300683) — Cash Flow Quality Index
Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Cash Flow Quality Index of 1.89x as of June 2022. Operating cash flow of CN¥21.11 Million exceeds net income of CN¥11.18 Million, indicating high earnings quality where cash backs reported profits. Also explore 300683 asset base for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Wuhan Hiteck Biological Pharma Co Ltd Cash Flow Quality Index (2013–2021)
Historical Cash Flow Quality Index for Wuhan Hiteck Biological Pharma Co Ltd across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Wuhan Hiteck Biological Pharma Co Ltd (300683) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Wuhan Hiteck Biological Pharma Co Ltd (2013–2021)
Year-by-year earnings quality comparison for Wuhan Hiteck Biological Pharma Co Ltd. For live market cap and the full company financial profile, see 300683 stock market capitalisation.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 0.40x | CN¥12.09 Million | CN¥30.01 Million | ▼ -60.9% |
| 2019 | 1.03x | CN¥63.03 Million | CN¥61.19 Million | ▲ +28.3% |
| 2018 | 0.80x | CN¥73.42 Million | CN¥91.46 Million | ▲ +36.4% |
| 2017 | 0.59x | CN¥83.08 Million | CN¥141.20 Million | ▼ -35.9% |
| 2016 | 0.92x | CN¥143.86 Million | CN¥156.74 Million | ▼ -52.2% |
| 2015 | 1.92x | CN¥159.89 Million | CN¥83.23 Million | ▲ +54.6% |
| 2014 | 1.24x | CN¥135.40 Million | CN¥108.97 Million | ▲ +25.6% |
| 2013 | 0.99x | CN¥76.82 Million | CN¥77.65 Million | — |